Physician profile
Michael Makar
NPI 1386105237
$2,216.22
in general payments reported to CMS, 2019-2025
18 companies · $979 in 2025
The $979 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $258 · 2023: $95.24 · 2024: $885 · 2025: $979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,958.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $765.41 | 2022-2025 | |
| Medtronic, INC. | $371.02 | 2022-2025 | Manoscan, Endoflip, Het |
| Boston Scientific Corporation | $271.06 | 2022-2024 | |
| Gilead Sciences, INC. | $124.02 | 2024 | Livdelzi |
| Madrigal Pharmaceuticals | $115.11 | 2024-2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $111.94 | 2025 | Voquezna |
| Janssen Biotech, INC. | $97.28 | 2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $74.05 | 2024-2025 | Eohilia, Entyvio |
| Ipsen Biopharmaceuticals, INC | $49.30 | 2025 | Iqirvo |
| Ardelyx, INC. | $40.66 | 2024-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $39.96 | 2024 | Terlivaz |
| Novo Nordisk INC | $36.65 | 2025 | Wegovy |
| Steris Corporation | $23.26 | 2025 | |
| Genzyme Corporation | $22.29 | 2025 | |
| Qol Medical, LLC | $19.06 | 2025 | Sucraid |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $18.96 | 2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.78 | 2025 | Xifaxan |
| Pfizer INC. | $17.41 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Makar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.